A study shows that combining dual immunotherapy with chemotherapy improves outcomes for metastatic non-squamous NSCLC patients with STK11 and KEAP1 mutations. Learn more ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

Oct. 8, 2024 — Engineers built a solar-powered desalination system that produces large quantities of clean water despite variations in sunlight throughout the day. Because it requires no extra ...

BerGenBio announces safety data from phase 1b portion of BGBC016 study in first-line NSCLC: Bergen, Norway Tuesday, October 8, 2024, 15:00 Hrs [IST] BerGenBio ASA, a clinical-stag ...

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient ...

A severe solar storm is headed to Earth that could stress power grids even more as the US deals with disruptions from Hurricane Milton that hit Florida .

The trial entitled “Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway- Deficient NSCLC” is a Phase I/II trial where Phase I is a dose escalation study establishing the ...